Comparison of the effects of peramivir and oseltamivir on the rise in platelet count in patients with or without proven influenza

Young gon Kim, Sun-Young Ko, Sung Woo Lee

Research output: Contribution to journalArticle

Abstract

Objective: Neuraminidase (sialidase) inhibitors are considered to delay platelet clearance through the inhibition of platelet desialylation. A novel neuraminidase inhibitor, peramivir, was recently approved for intravenous administration by the US FDA. We aimed to compare the effects of peramivir and oseltamivir on patient platelet count. Materials and methods: Consecutive patients who were treated with peramivir or tested positive for influenza between January 2015 and December 2017 were analyzed. The analysis included 461 patients with platelet counts available; the patients were divided into three groups: patients with proven influenza treated with peramivir (n = 305); those treated with peramivir without proven influenza (n = 83), and those with proven influenza treated with oseltamivir (n = 73). Results: Patients treated with peramivir did not show an increase in platelet count from the baseline count, regardless of proven influenza (from 263.4 × 10 9 /L to 267.4 × 10 9 /L; 9 = 0.410) or not (from 257.1 × 10 9 /L to 255.4 × 10 9 /L; p = 0.873); wheeras for patients treated with oseltamivir, a significant increase above the baseline was found (from 223.3 × 10 9 /L to 249.9 × 10 9 /L; p = 0.016), although it was transient. Conclusion: Peramivir and oseltamivir appear to have different effects on patient platelet count when administered at the recommended doses.

Original languageEnglish
Pages (from-to)152-159
Number of pages8
JournalInternational Journal of Clinical Pharmacology and Therapeutics
Volume57
Issue number3
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Oseltamivir
Platelet Count
Human Influenza
Neuraminidase
Blood Platelets
peramivir
Intravenous Administration

Keywords

  • Dase inhibitor
  • Neuramini
  • Oseltamivir
  • Peramivir
  • Platelet

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{4abcb2db21d44377ab368df600340904,
title = "Comparison of the effects of peramivir and oseltamivir on the rise in platelet count in patients with or without proven influenza",
abstract = "Objective: Neuraminidase (sialidase) inhibitors are considered to delay platelet clearance through the inhibition of platelet desialylation. A novel neuraminidase inhibitor, peramivir, was recently approved for intravenous administration by the US FDA. We aimed to compare the effects of peramivir and oseltamivir on patient platelet count. Materials and methods: Consecutive patients who were treated with peramivir or tested positive for influenza between January 2015 and December 2017 were analyzed. The analysis included 461 patients with platelet counts available; the patients were divided into three groups: patients with proven influenza treated with peramivir (n = 305); those treated with peramivir without proven influenza (n = 83), and those with proven influenza treated with oseltamivir (n = 73). Results: Patients treated with peramivir did not show an increase in platelet count from the baseline count, regardless of proven influenza (from 263.4 × 10 9 /L to 267.4 × 10 9 /L; 9 = 0.410) or not (from 257.1 × 10 9 /L to 255.4 × 10 9 /L; p = 0.873); wheeras for patients treated with oseltamivir, a significant increase above the baseline was found (from 223.3 × 10 9 /L to 249.9 × 10 9 /L; p = 0.016), although it was transient. Conclusion: Peramivir and oseltamivir appear to have different effects on patient platelet count when administered at the recommended doses.",
keywords = "Dase inhibitor, Neuramini, Oseltamivir, Peramivir, Platelet",
author = "Kim, {Young gon} and Sun-Young Ko and Lee, {Sung Woo}",
year = "2019",
month = "1",
day = "1",
doi = "10.5414/CP203366",
language = "English",
volume = "57",
pages = "152--159",
journal = "International Journal of Clinical Pharmacology and Therapeutics",
issn = "0946-1965",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "3",

}

TY - JOUR

T1 - Comparison of the effects of peramivir and oseltamivir on the rise in platelet count in patients with or without proven influenza

AU - Kim, Young gon

AU - Ko, Sun-Young

AU - Lee, Sung Woo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: Neuraminidase (sialidase) inhibitors are considered to delay platelet clearance through the inhibition of platelet desialylation. A novel neuraminidase inhibitor, peramivir, was recently approved for intravenous administration by the US FDA. We aimed to compare the effects of peramivir and oseltamivir on patient platelet count. Materials and methods: Consecutive patients who were treated with peramivir or tested positive for influenza between January 2015 and December 2017 were analyzed. The analysis included 461 patients with platelet counts available; the patients were divided into three groups: patients with proven influenza treated with peramivir (n = 305); those treated with peramivir without proven influenza (n = 83), and those with proven influenza treated with oseltamivir (n = 73). Results: Patients treated with peramivir did not show an increase in platelet count from the baseline count, regardless of proven influenza (from 263.4 × 10 9 /L to 267.4 × 10 9 /L; 9 = 0.410) or not (from 257.1 × 10 9 /L to 255.4 × 10 9 /L; p = 0.873); wheeras for patients treated with oseltamivir, a significant increase above the baseline was found (from 223.3 × 10 9 /L to 249.9 × 10 9 /L; p = 0.016), although it was transient. Conclusion: Peramivir and oseltamivir appear to have different effects on patient platelet count when administered at the recommended doses.

AB - Objective: Neuraminidase (sialidase) inhibitors are considered to delay platelet clearance through the inhibition of platelet desialylation. A novel neuraminidase inhibitor, peramivir, was recently approved for intravenous administration by the US FDA. We aimed to compare the effects of peramivir and oseltamivir on patient platelet count. Materials and methods: Consecutive patients who were treated with peramivir or tested positive for influenza between January 2015 and December 2017 were analyzed. The analysis included 461 patients with platelet counts available; the patients were divided into three groups: patients with proven influenza treated with peramivir (n = 305); those treated with peramivir without proven influenza (n = 83), and those with proven influenza treated with oseltamivir (n = 73). Results: Patients treated with peramivir did not show an increase in platelet count from the baseline count, regardless of proven influenza (from 263.4 × 10 9 /L to 267.4 × 10 9 /L; 9 = 0.410) or not (from 257.1 × 10 9 /L to 255.4 × 10 9 /L; p = 0.873); wheeras for patients treated with oseltamivir, a significant increase above the baseline was found (from 223.3 × 10 9 /L to 249.9 × 10 9 /L; p = 0.016), although it was transient. Conclusion: Peramivir and oseltamivir appear to have different effects on patient platelet count when administered at the recommended doses.

KW - Dase inhibitor

KW - Neuramini

KW - Oseltamivir

KW - Peramivir

KW - Platelet

UR - http://www.scopus.com/inward/record.url?scp=85061868903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061868903&partnerID=8YFLogxK

U2 - 10.5414/CP203366

DO - 10.5414/CP203366

M3 - Article

VL - 57

SP - 152

EP - 159

JO - International Journal of Clinical Pharmacology and Therapeutics

JF - International Journal of Clinical Pharmacology and Therapeutics

SN - 0946-1965

IS - 3

ER -